Results 1 to 10 of about 5,472 (197)
Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging [PDF]
JHEP ReportsBackground & aims: Terlipressin improves renal function in ∼40% of patients with hepatorenal syndrome–acute kidney injury (HRS-AKI). Nonetheless, the pathophysiological mechanisms of terlipressin remain unclear.
Karen Vagner Danielsen +10 more
doaj +2 more sources
The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review [PDF]
BMC AnesthesiologyBackground Intraoperative hypotension is a recognized risk factor for delayed graft function (DGF) after kidney transplantation and may compromise both short- and long-term allograft outcomes.
Wen-He Yang +6 more
doaj +2 more sources
Hyponatraemia Induced by Terlipressin in Patients Diagnosed with Decompensated Liver Cirrhosis and Acute Variceal Bleeding [PDF]
MedicinesBackground: Hyponatraemia is a rare but potentially life-threatening complication of terlipressin therapy. Case history: In the current case, a 39-year-old female with decompensated liver cirrhosis (Child-Pugh C) and acute variceal bleeding experienced a
Mahmoud Elshehawy +4 more
doaj +2 more sources
Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease [PDF]
BMC GastroenterologyBackground and aims Intestinal paralysis is a common complication in end-stage liver disease (ESLD), our aim is to assess the effectiveness and safety of low-dose terlipressin for treating intestinal paralysis in ESLD.
Xia Wan +7 more
doaj +2 more sources
Annals of Hepatology, 2023 Introduction and Objectives: Clinical data for older patients with advanced liver disease are limited. This post hoc analysis evaluated the efficacy and safety of terlipressin in patients aged ≥65 years with hepatorenal syndrome using data from 3 Phase ...
Muhammad A. Mujtaba +8 more
doaj +1 more source
Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome
AAPS Open, 2022 The objective of this population pharmacokinetics (PK) analysis was to characterize the PK of terlipressin and its active metabolite, lysine-vasopressin (L-VP), in patients with hepatorenal syndrome (HRS), following intravenous administration of ...
Xiaofeng Wang, Khurram Jamil
doaj +1 more source
Canadian Journal of Gastroenterology and Hepatology, 2020 Ascites, a common complication in cirrhosis, is prone to the development of acute kidney injury or hepatorenal syndrome and can be complicated by circulatory dysfunction after paracentesis.
Zhaohui Bai +6 more
doaj +1 more source
Ain Shams Journal of Anesthesiology, 2020 Background and objectives Preoperative use of renin angiotensin system antagonists has been considered an independent risk factor for development of vasoplegic syndrome.
Mohamed Saleh +2 more
doaj +1 more source
Intensivmedizin und Notfallmedizin, 2005 The vasopressing agent terlipressin is a commonly used drug with various indications especially in patients with advanced cirrhosis. Being a potent vasoconstrictor it increases the systemic vascular pressure especially inthe splanchnic area, resulting in a decrease of portal pressure. Due to complex pathophysiologic patterns, different complications of
T. Brünnler +2 more
openaire +2 more sources
Scientific Reports, 2022 Terlipressin with albumin, the recommended treatment for hepatorenal syndrome-acute kidney injury (HRS-AKI), is associated with adverse events. Furthermore, the course of AKI in patients with acute-on-chronic liver failure (ACLF) is unknown.
Anand V. Kulkarni +8 more
doaj +1 more source